Abstract
Objective: Serotonin 1A receptor (HTR1A) is a candidate molecule for influencing the pathophysiology of major depressive disorder (MDD) and clinical responses to antidepressant treatment. Among polymorphisms of the HTR1A gene, -1019C>G (rs6295) is reportedly a biologically functional polymorphism associated with response to antidepressant treatment. The aim of this study was to determine the relationship between the HTR1A-1019C>G polymorphism and the response to escitalopram in patients with MD. Method: Eighty Korean patients were examined using the Structured Clinical Interview for DSM-IV Axis I disorders and took escitalopram at a daily dose of 5 to 40 mg. Clinical symptoms were evaluated using the 21-item Hamilton Depression Rating (HAM-D) scale during 8 weeks of treatment. The genotypes were determined using HpyCH4 IV digestion following polymerase chain reaction. Results: The proportion of G-allele carriers was 25.0% in responders, which was lower than that in non-responders (53.9%) at 1 week of escitalopram treatment (OR = 0.28, P = 0.030). In allelic analysis, the frequency of the G allele was significantly lower in responders at 1 week than in non-responders (12.5% versus 31.7%, respectively; OR = 0.29, P = 0.029). Similarly, the ratio of HAM-D score at 1 week to the baseline score in C-allele carriers was 67.6% ± 2.42%, which was significantly lower than the ratio of 75.8% ± 2.74% in patients possessing the G allele (P = 0.027). Conclusions: Although this study is preliminary and has several limitations, our results suggest that HTR1A- 1019C>G may be a genetic marker predicting the response to escitalopram treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 148-154 |
| Number of pages | 7 |
| Journal | Clinical Neuropsychiatry |
| Volume | 10 |
| Issue number | 3-4 |
| Publication status | Published - 2013 Oct 10 |
Fingerprint
Keywords
- Escitalopram
- Major depressive disorder
- Serotonin receptor 1A
- Single-nucleotide polymorphism
- Treatment response
ASJC Scopus subject areas
- Psychiatry and Mental health
Cite this
Relationship between the serotonin receptor 1A polymorphism with treatment response to escitalopram in patients with major depresive disorder. / Soo Chang, Hun; Choi, In Kwang; Lee, Hwa Young; Jeong, Yoo Jung; Kim, Bohye; Lee, Min-Soo.
In: Clinical Neuropsychiatry, Vol. 10, No. 3-4, 10.10.2013, p. 148-154.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Relationship between the serotonin receptor 1A polymorphism with treatment response to escitalopram in patients with major depresive disorder
AU - Soo Chang, Hun
AU - Choi, In Kwang
AU - Lee, Hwa Young
AU - Jeong, Yoo Jung
AU - Kim, Bohye
AU - Lee, Min-Soo
PY - 2013/10/10
Y1 - 2013/10/10
N2 - Objective: Serotonin 1A receptor (HTR1A) is a candidate molecule for influencing the pathophysiology of major depressive disorder (MDD) and clinical responses to antidepressant treatment. Among polymorphisms of the HTR1A gene, -1019C>G (rs6295) is reportedly a biologically functional polymorphism associated with response to antidepressant treatment. The aim of this study was to determine the relationship between the HTR1A-1019C>G polymorphism and the response to escitalopram in patients with MD. Method: Eighty Korean patients were examined using the Structured Clinical Interview for DSM-IV Axis I disorders and took escitalopram at a daily dose of 5 to 40 mg. Clinical symptoms were evaluated using the 21-item Hamilton Depression Rating (HAM-D) scale during 8 weeks of treatment. The genotypes were determined using HpyCH4 IV digestion following polymerase chain reaction. Results: The proportion of G-allele carriers was 25.0% in responders, which was lower than that in non-responders (53.9%) at 1 week of escitalopram treatment (OR = 0.28, P = 0.030). In allelic analysis, the frequency of the G allele was significantly lower in responders at 1 week than in non-responders (12.5% versus 31.7%, respectively; OR = 0.29, P = 0.029). Similarly, the ratio of HAM-D score at 1 week to the baseline score in C-allele carriers was 67.6% ± 2.42%, which was significantly lower than the ratio of 75.8% ± 2.74% in patients possessing the G allele (P = 0.027). Conclusions: Although this study is preliminary and has several limitations, our results suggest that HTR1A- 1019C>G may be a genetic marker predicting the response to escitalopram treatment.
AB - Objective: Serotonin 1A receptor (HTR1A) is a candidate molecule for influencing the pathophysiology of major depressive disorder (MDD) and clinical responses to antidepressant treatment. Among polymorphisms of the HTR1A gene, -1019C>G (rs6295) is reportedly a biologically functional polymorphism associated with response to antidepressant treatment. The aim of this study was to determine the relationship between the HTR1A-1019C>G polymorphism and the response to escitalopram in patients with MD. Method: Eighty Korean patients were examined using the Structured Clinical Interview for DSM-IV Axis I disorders and took escitalopram at a daily dose of 5 to 40 mg. Clinical symptoms were evaluated using the 21-item Hamilton Depression Rating (HAM-D) scale during 8 weeks of treatment. The genotypes were determined using HpyCH4 IV digestion following polymerase chain reaction. Results: The proportion of G-allele carriers was 25.0% in responders, which was lower than that in non-responders (53.9%) at 1 week of escitalopram treatment (OR = 0.28, P = 0.030). In allelic analysis, the frequency of the G allele was significantly lower in responders at 1 week than in non-responders (12.5% versus 31.7%, respectively; OR = 0.29, P = 0.029). Similarly, the ratio of HAM-D score at 1 week to the baseline score in C-allele carriers was 67.6% ± 2.42%, which was significantly lower than the ratio of 75.8% ± 2.74% in patients possessing the G allele (P = 0.027). Conclusions: Although this study is preliminary and has several limitations, our results suggest that HTR1A- 1019C>G may be a genetic marker predicting the response to escitalopram treatment.
KW - Escitalopram
KW - Major depressive disorder
KW - Serotonin receptor 1A
KW - Single-nucleotide polymorphism
KW - Treatment response
UR - http://www.scopus.com/inward/record.url?scp=84885042242&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885042242&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84885042242
VL - 10
SP - 148
EP - 154
JO - Clinical Neuropsychiatry
JF - Clinical Neuropsychiatry
SN - 1724-4935
IS - 3-4
ER -